Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Key Points
B Group bought 67,500 shares of Bright Minds Biosciences in the first quarter.
The quarter-end value of the new stake was $4.93 million.
Transaction value equates to 4% of B Group, Inc.’s reportable U.S. equity assets
The new position, while notable, places Bright Minds Biosciences outside the fund’s top five holdings.
- 10 stocks we like better than Bright Minds Biosciences ›
B Group, Inc. disclosed a new stake in Bright Minds Biosciences (NASDAQ:DRUG) in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing.
What happened
According to a May 15, 2026, SEC filing, B Group, Inc. initiated a new position in Bright Minds Biosciences, purchasing 67,500 shares. The estimated transaction value is $5.43 million, calculated using the average closing price for the first quarter of 2026. The value of the stake at quarter-end was $4.93 million, a figure that includes both share purchases and movement in the company’s stock price during the period.
What else to know
- This is a new position for B Group, Inc., representing roughly 4% of reportable AUM as of March 31, 2026.
- Top five holdings after the filing:
- NASDAQ: ADMA: $28.90 million (21.4% of AUM)
- NASDAQ: PALI: $19.97 million (14.8% of AUM)
- NASDAQ: PRAX: $10.71 million (7.9% of AUM)
- NASDAQ: CLLS: $10.40 million (7.7% of AUM)
- NASDAQ: ZLAB: $8.48 million (6.3% of AUM)
- As of Thursday, Bright Minds Biosciences shares were priced at $83.24, up nearly 175% over the past year and well outperforming the S&P 500, which is instead up about 25%.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close May 14, 2026) | $83.24 |
| Market Capitalization | $815 million |
| Net Income (TTM) | ($19.8 million) |
Company Snapshot
- DRUG develops selective 5-HT receptor agonists targeting epilepsy, pain, and neuropsychiatric disorders, with a portfolio focused on 5-HT2C, 5-HT2A, and 5-HT2C/A compounds.
- The firm operates a pre-clinical biotechnology model, generating value through research collaborations and intellectual property development rather than product sales.
- It targets patients with severe neurological and psychiatric conditions, collaborating with research institutions and healthcare partners to advance clinical applications.
Bright Minds Biosciences is a pre-clinical biotechnology company specializing in the development of next-generation serotonin-based therapeutics for neurological and neuropsychiatric conditions. The company leverages strategic collaborations with leading medical research institutions to accelerate innovation and expand its intellectual property portfolio. With a focus on high unmet medical needs, Bright Minds aims to establish a competitive edge through targeted drug development and scientific partnerships.
What this transaction means for investors
B Group is stepping into Bright Minds during a massive run higher, suggesting it sees additional upside tied to the company's drug pipeline (given the nature of pre-revenue biotechs). The company's most important asset remains BMB-101, a serotonin receptor agonist being developed for drug-resistant epilepsies. Management has been accelerating development efforts, with research and development spending climbing to C$18.7 million during the first six months of fiscal 2026, up from C$3.6 million a year earlier as clinical and preclinical programs advanced.
Just as important, Bright Minds ended March with roughly C$309.7 million in cash and cash equivalents after completing a January equity offering that raised about $175 million. That gives the company substantial resources to fund development without the near-term financing pressure that often weighs on early-stage biotech firms. For long-term investors, this is still a high-risk, high-reward story. The company has no commercial revenue and remains loss-making. But with a well-funded balance sheet and pipeline progress, there are reasons to be bullish.
Should you buy stock in Bright Minds Biosciences right now?
Before you buy stock in Bright Minds Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bright Minds Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,063!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,369,991!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 21, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adma Biologics. The Motley Fool has a disclosure policy.
Recommended Articles
